mRNA Cancer Therapies Face U.S. Curbs Despite 90% Pancreatic Survival and Phase III Melanoma Win
Updated
Updated · RealClearHealth · Sep 19
mRNA Cancer Therapies Face U.S. Curbs Despite 90% Pancreatic Survival and Phase III Melanoma Win
3 articles · Updated · RealClearHealth · Sep 19
Summary
Late-stage mRNA cancer results are colliding with U.S. political backlash: a Phase III melanoma trial succeeded, while personalized treatments also showed promise in glioblastoma and pancreatic cancer.
Advanced melanoma patients given an individualized mRNA therapy plus immunotherapy saw recurrence or death risk cut significantly, marking the first mRNA cancer medicine to clear a Phase III study.
Pancreatic cancer data showed nearly 90% of patients alive up to six years at Memorial Sloan Kettering, versus a 13% five-year survival rate for the disease; an early glioblastoma trial also triggered anti-tumor immune responses.
State lawmakers in Montana, Minnesota and Texas sought mRNA restrictions this year, and some companies and research institutions developing the treatments lost federal funding amid lingering COVID-era mistrust.
China signed $135.7 billion in biotech out-licensing deals in 2025 and now registers more clinical trials than the U.S., raising the risk that American limits could shift both therapies and jobs overseas.